| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 0 | 0 | 0 | 0 | 15,070 |
| Sales Growth | unch | unch | unch | -100.00% | -37.70% |
| Net Income | -3,030 | -1,220 | -990 | -1,270 | 4,340 |
| Net Income Growth | -148.36% | -23.23% | +22.05% | -129.26% | +190.99% |
Special Diversified Opportunities Inc (SDOI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Special Diversified Opportunities Inc is a Delaware corporation Incorporated in 1990. The Life Sciences Business constituted its only operating business, and accordingly, following the closing of the Asset Sale, the Company has become a 'shell company' under the federal securities laws. Prior to the completion of the Asset Sale, the Company was a biotechnology company engaged in developing, commercializing and marketing proprietary products, services and solutions that preserve and enhance the quality of human health and wellness. The Company provided various life sciences products and services, including custom antibodies, in-vitro diagnostic-grade antibodies, proprietary critical reagent products, associated bio-processing services, and custom assay design and development services. The Company's products and services were sold to, and often incorporated in the production process for other commercial products used by various customers including pharmaceutical, biotechnology and diagnostic companies, and major biomedical research centers both domestically and internationally. The Company's Genomic Antibody Technology ('GAT') was used in proteomic research, disease understanding and drug/biomarker discovery among academic, biotech, in-vitro diagnostic ('IVD') and pharmaceutical customers.